Trials / Completed
CompletedNCT02784171
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 520 (actual)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer. Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth and/or spreading of cancer.
Detailed description
The purpose of this study is to find out what effects a new drug, pembrolizumab has on this type of cancer and if it can offer better results than standard pemetrexed and platinum-based chemotherapy alone. This study will also look at side effects and how the treatments impact quality of life
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin | |
| DRUG | Pemetrexed | |
| DRUG | Pembrolizumab |
Timeline
- Start date
- 2016-11-11
- Primary completion
- 2024-10-11
- Completion
- 2024-10-11
- First posted
- 2016-05-26
- Last updated
- 2024-12-10
- Results posted
- 2024-12-10
Locations
57 sites across 3 countries: Canada, France, Italy
Source: ClinicalTrials.gov record NCT02784171. Inclusion in this directory is not an endorsement.